Refanezumab
Modify Date: 2024-01-02 10:30:39
Refanezumab structure
|
Common Name | Refanezumab | ||
|---|---|---|---|---|
| CAS Number | 1233953-61-1 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of RefanezumabRefanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2]. |
| Name | Refanezumab |
|---|
| Description | Refanezumab (GSK249320) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier (BBB) in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke[1][2]. |
|---|---|
| Related Catalog | |
| In Vivo | Refanezumab (GSK249320; 10 mg/kg; 静脉给药; 在中风后 24 小时开始并每周继续给药 6 次) 显示神经评分和阶梯测试有更大的增加。Refanezumab 通过静脉注射后，可穿透病变部位，并且在中风后 24 小时对功能结果有轻微影响。 Animal Model: Male Sprague Dawley rats (weight 361g)[1]10 mg/kg IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more dosesAnimals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit. Dosage: 10 mg/kg Administration: IV; starting 24 hours post-stroke and continuing weekly for 6 more doses; starting seven days post-stroke and continuing weekly for 5 more doses Result: Animals treated 24 hours post-stroke showed larger increases in neuroscore and staircase test as compared to controls, but animals treated 7 days post-stroke showed no significant behavioral benefit. |
| References |
| No Any Chemical & Physical Properties |